baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Company profile
Ticker
BAX
Exchange
Website
CEO
Jose Almeida
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Baxter Corporation • Baxter Healthcare Corporation • Baxter Healthcare of Puerto Rico LLC • Baxter Pharmaceutical Solutions LLC • Baxter Sales and Distribution LLC • Cheetah Medical, Inc. • Gambro Renal Products, Inc. • Gambro UF Solutions, Inc. • Hill-Rom Holdings, Inc • Laboratorios Baxter S.A. ...
IRS number
360781620
BAX stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEFA14A
Additional proxy soliciting materials
25 Mar 24
DEF 14A
Definitive proxy
25 Mar 24
8-K
Entry into a Material Definitive Agreement
21 Mar 24
PRE 14A
Preliminary proxy
14 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
10-K
2023 FY
Annual report
8 Feb 24
8-K
Baxter Reports Fourth-quarter and Full-year 2023 Results
8 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Baxter Reports Third-quarter 2023 Results
2 Nov 23
Transcripts
BAX
Earnings call transcript
2023 Q4
8 Feb 24
BAX
Earnings call transcript
2023 Q3
2 Nov 23
BAX
Earnings call transcript
2023 Q2
27 Jul 23
BAX
Earnings call transcript
2023 Q1
27 Apr 23
BAX
Earnings call transcript
2022 Q4
9 Feb 23
BAX
Earnings call transcript
2022 Q3
27 Oct 22
BAX
Earnings call transcript
2022 Q2
28 Jul 22
BAX
Earnings call transcript
2022 Q1
28 Apr 22
BAX
Earnings call transcript
2021 Q4
17 Feb 22
BAX
Earnings call transcript
2021 Q3
28 Oct 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.79 bn | 5.79 bn | 5.79 bn | 5.79 bn | 5.79 bn | 5.79 bn |
Cash burn (monthly) | (no burn) | (no burn) | 57.33 mm | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 342.91 mm | n/a | n/a | n/a |
Cash remaining | n/a | n/a | 5.45 bn | n/a | n/a | n/a |
Runway (months of cash) | n/a | n/a | 95.0 | n/a | n/a | n/a |
Institutional ownership, Q3 2023
86.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 882 |
Opened positions | 89 |
Closed positions | 153 |
Increased positions | 273 |
Reduced positions | 366 |
13F shares | Current |
---|---|
Total value | 16.56 tn |
Total shares | 438.96 mm |
Total puts | 2.87 mm |
Total calls | 7.09 mm |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 65.35 mm | $2.47 tn |
Vanguard | 60.33 mm | $2.28 tn |
STT State Street | 20.90 mm | $794.83 bn |
T. Rowe Price | 17.16 mm | $649.19 bn |
JPM JPMorgan Chase & Co. | 15.97 mm | $602.70 bn |
IVZ Invesco | 11.60 mm | $437.78 bn |
AMP Ameriprise Financial | 10.84 mm | $408.99 bn |
Geode Capital Management | 10.83 mm | $407.95 bn |
Dodge & Cox | 9.85 mm | $371.68 bn |
MCQEF Macquarie | 8.36 mm | $315.52 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Toth Christopher A. | Common Stock, $1 par value | Grant | Acquire A | No | No | 0 | 119,076 | 0.00 | 227,761 |
6 Mar 24 | Stevens Brian | Common Stock, $1 par value | Grant | Acquire A | No | No | 0 | 14,289 | 0.00 | 67,538 |
6 Mar 24 | Alok Sonig | Common Stock, $1 par value | Grant | Acquire A | No | No | 0 | 83,353 | 0.00 | 113,454 |
6 Mar 24 | David S. Rosenbloom | Common Stock, $1 par value | Grant | Acquire A | No | No | 0 | 53,584 | 0.00 | 108,989 |
6 Mar 24 | Reaz Rasul | Common Stock, $1 par value | Grant | Acquire A | No | No | 0 | 83,353 | 0.00 | 109,187 |
News
10 Health Care Stocks With Whale Alerts In Today's Session
20 Mar 24
Why Are Dialysis Provider Stocks Trading Higher On Tuesday?
5 Mar 24
B of A Securities Maintains Neutral on Baxter Intl, Raises Price Target to $45
5 Mar 24
Spectral Medical Announces Amendment And Extension Of Exclusive Supply And Distribution Agreement With Baxter Healthcare Corporation
21 Feb 24
Barclays Maintains Overweight Rating for Baxter Intl: Here's What You Need To Know
12 Feb 24
Press releases
Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation
21 Feb 24
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients
15 Feb 24
Baxter Declares Quarterly Dividend
12 Feb 24
Baxter Reports Fourth-Quarter and Full-Year 2023 Results
8 Feb 24
Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors
4 Jan 24